Optimizing the Cost-Effective Evaluation of Gastroesophageal Reflux by Typical Symptom Phenotypes After Failure of Empiric Acid Suppression Trial
- PMID: 40471840
- PMCID: PMC12354272
- DOI: 10.14309/ajg.0000000000003576
Optimizing the Cost-Effective Evaluation of Gastroesophageal Reflux by Typical Symptom Phenotypes After Failure of Empiric Acid Suppression Trial
Abstract
Introduction: Concern for gastroesophageal reflux disease (GERD) is the most common reason to consult gastroenterology. We aimed to optimize routine GERD evaluation on cost-effectiveness according to the dominant typical symptom among patients with persistent symptoms failing empiric proton-pump inhibitors (PPI).
Methods: We developed a decision analytic model evaluating all permutations of GERD diagnostics including empiric trials of PPI optimization or discontinuation, upper endoscopy, wireless pH-monitoring, and pH-impedance monitoring. The model was applied to patients with heartburn, regurgitation, and chest pain in general gastroenterology to identify the appropriate combination and order of testing from insurer and patient perspectives. Health outcomes were informed by systematic reviews of clinical trials. Cost outcomes were informed by Centers for Medicare and Medicaid Services and commercial datasets and national observational studies. The time horizon was 1 year, and willingness-to-pay threshold was $100,000/quality-adjusted life year gained.
Results: For patients with typical persistent GERD symptoms failing empiric PPI, routine up-front ambulatory reflux testing saved $2,500-$4,500 compared with endoscopy alone when no erosive esophagitis is found. The most cost-effective initial ambulatory reflux test was 96-hour wireless pH-monitoring for patients with heartburn and chest pain and 24-hour pH-impedance monitoring for patients with regurgitation, both performed OFF-PPI. Adding ON-PPI pH-impedance monitoring optimized cost-effectiveness for patients with documented evidence of GERD and PPI-refractory symptoms. Patient and insurer perspectives aligned on these optimal diagnostic strategies.
Discussion: Compared with a one-size-fits-all strategy, a tailored approach based on Lyon 2.0 optimizes cost-effective evaluation and management of GERD by phenotyping the appropriate diagnostics to dominant symptom.
Keywords: EGD; GERD; diagnostic testing; gastroesophageal reflux; hiatal hernia; insurance coverage; pH acid monitoring; patient preference; shared decision making; upper endoscopy.
Copyright © 2025 by The American College of Gastroenterology.
Conflict of interest statement
Potential competing interests: EDS consulted for Salix, Mahana, Neuraxis, Phathom, Takeda, Ardelyx, Sanofi, and GI Supply. CPG consulted for Medtronic, Braintree, Phathom and is on the speaker bureau for Carnot. WWC consulted for Regeneron.
Similar articles
-
Italian guidelines for the diagnosis and management of gastro-esophageal reflux disease: Joint consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), and General Medicine (SIMG).Dig Liver Dis. 2025 Aug;57(8):1550-1577. doi: 10.1016/j.dld.2025.04.020. Epub 2025 May 30. Dig Liver Dis. 2025. PMID: 40450492
-
Latin American consensus on diagnosis of gastroesophageal reflux disease.Neurogastroenterol Motil. 2024 Mar;36(3):e14735. doi: 10.1111/nmo.14735. Epub 2024 Jan 15. Neurogastroenterol Motil. 2024. PMID: 38225792 Free PMC article.
-
Optimizing the Management Algorithm for Heartburn in General Gastroenterology: Cost-Effectiveness and Cost-Minimization Analysis.Clin Gastroenterol Hepatol. 2024 Oct;22(10):2011-2022.e5. doi: 10.1016/j.cgh.2023.08.026. Epub 2023 Sep 7. Clin Gastroenterol Hepatol. 2024. PMID: 37683879
-
Safety and efficacy of proton pump inhibitors in preterm infants with gastroesophageal reflux disease.Cochrane Database Syst Rev. 2025 Mar 11;3(3):CD015127. doi: 10.1002/14651858.CD015127.pub2. Cochrane Database Syst Rev. 2025. PMID: 40066936
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
References
-
- Tack J, Pandolfino JE. Pathophysiology of Gastroesophageal Reflux Disease. Gastroenterology 2018;154:277–288. - PubMed
-
- Moshiree B, Drossman D, Shaukat A. AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review. Gastroenterology 2023;165:791–800.e3. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous